The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday share tips: Whitbread, Petra Diamonds, Empiric Student Property

Sun, 15th Jun 2014 12:28

Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coffee. Some analysts fear Costa has reached saturation point but Barclays thinks Whitbread shares could rise from £42 to £70 as it starts to reap rewards from overseas investment. A second, cheaper hotel brand called Hub could also ease worries about growth prospects. The stock could pause for breath but it looks like a decent long-term bet.Buy Petra Diamonds, Questor recommended in the Sunday Telegraph. The shares are up 51% since Questor recommended them in September and following the discovery of a walnut-sized blue diamond the tipster is sticking by its opinion. The potential price Petra will receive for selling the gem could wipe out Petra's debt as it invests in upgrading its old mines. It has already said that production in the first nine months of its financial year was up 26%.Buy Empiric Student Property when it floats this week to tap into demand for more upmarket student housing, Midas advised in the Mail on Sunday. The management team will use £80m of the flotation proceeds to buy 11 properties to add to its existing fully occupied housing. In the UK's 27 top university cities, 96% of non-first years have no access to purpose-built housing. Many are prepared to pay to be near city centres, including 300,000 international students. Investors can expect a 6% dividend yield in the first year and capital growth as rents rise and development properties come into use.St Ives' shares have had a strong run and the media group is trading at levels not seen since before Lehman Brothers went bust in 2008, Matthew Goodman wrote in the Sunday Times. The company has transformed itself from printing books and annual reports into a media consultancy, advising on digital marketing and other things. St Ives has grown through acquisitions, leaving questions about its strategy, but its imminent trading update should reassure investors of the logic in its deals.Steer clear of PZ Cussons, the maker of Imperial Leather soap, Questor advised in the Sunday Telegraph. It is a quality company for the long term, withstanding recessions and rewarding investors through its dividend. But the shares are looking expensive, especially with growth slowing in Africa and Asia, where it makes about half its operating profits. Its expected annual profit would have been up to £12m higher without the impact of falling emerging markets currencies. Take some profit from Synairgen's success but do not sell out of the biotech company entirely, Midas said in the Mail on Sunday. The shares jumped by 20p to 70p last week when Synairgen signed a $238m deal with AstraZeneca for Astra to develop and sell its treatment to help asthma and emphysema sufferers who have a cold or flu. Midas recommended the shares at 28p in January 2010 and at 39p two years ago. There is plenty more upside for investors when the potential blockbuster drug goes on sale in a few years.Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.SF
More News
8 Sep 2020 19:32

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

Read more
8 Sep 2020 15:16

Synairgen upbeat on latest data from SNG001 trials

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced positive data from the interim analysis of its exploratory phase 2 clinical trial of inhaled 'SNG001' on Tuesday, in chronic obstructive pulmonary disease (COPD) patients with a confirmed respiratory viral infection.

Read more
21 Jul 2020 15:51

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

Read more
20 Jul 2020 20:23

COVID SCIENCE-Multiple vaccine candidates show early promise; inhaled interferon helps severe COVID-19 patients

By Nancy LapidJuly 20 (Reuters) - The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Early tests of COVID-19 ...

Read more
20 Jul 2020 16:55

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

Read more
20 Jul 2020 11:54

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Read more
20 Jul 2020 09:10

REFILE-UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

(Refiles to correct spelling in the media identifier)* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasmBy Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold ...

Read more
20 Jul 2020 09:10

UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasm (Recasts, adds comment from CEO and academic expert)By Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold...

Read more
20 Jul 2020 09:10

UPDATE 1-Synairgen shares soar as drug shows lower risk of severe COVID-19 cases

(Adds details on the trial, shares)July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of severe cases in hospitalised patients with COVID-19, according to data from a trial of more than 100 people in the United Kingdo...

Read more
20 Jul 2020 07:56

Europe open: Stocks reverse early losses, healthcare leads

(Sharecast News) - Stocks have recovered from early selling following news that European Union leaders meeting in Brussels had made progress on the terms for a reconstruction fund.

Read more
20 Jul 2020 07:56

Synairgen's drug shows reduced risk of severe disease in COVID-19 patients

July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.The trial, which used in...

Read more
20 Jul 2020 07:20

Synairgen treatment reduces risk of 'severe' Covid-19 by 79%

(Sharecast News) - Synairgen's Covid-19 treatment sharply reduced the risk of patients developing severe forms of the illness provoked by the novel coronavirus, clinical trials showed.

Read more
22 Jun 2020 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Jun 2020 17:59

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

Read more
18 Jun 2020 09:12

Synairgen expands Covid-19 trial nationwide

(Sharecast News) - Synairgen is to expand trials of a potential treatment for Covid-19 nationally, the respiratory drug specialist said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.